Matches in Nanopublications for { ?s ?p "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP211421.RAD75srY4AMzkftU5B6sQZgEv083rSdx9c4UDuslazuDY130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP211421.RAD75srY4AMzkftU5B6sQZgEv083rSdx9c4UDuslazuDY130_provenance.
- NP329160.RAEUr6rFXWsIhkVUyq5UivEck6yPtXwHANSIbcxavJK5Q130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329160.RAEUr6rFXWsIhkVUyq5UivEck6yPtXwHANSIbcxavJK5Q130_provenance.
- NP461826.RAzGkDnRboufmfJ0QO8kH8AtOslWsvHOWVNlncaFMzOW0130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP461826.RAzGkDnRboufmfJ0QO8kH8AtOslWsvHOWVNlncaFMzOW0130_provenance.
- NP612027.RA8u9pS1bgDOVRi9Oi0OC_KBgGt799sX1mVlKS2TCyWRg130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612027.RA8u9pS1bgDOVRi9Oi0OC_KBgGt799sX1mVlKS2TCyWRg130_provenance.
- NP983724.RAaztpSWLIN1MCl-Mx4PKDQ8MtQa0qi9gUX6VDGaEyr2A130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP983724.RAaztpSWLIN1MCl-Mx4PKDQ8MtQa0qi9gUX6VDGaEyr2A130_provenance.
- assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP733343.RAX_qLHaruwRY0xLFfGNIm4SDUCSdeQHtRt3hJrhcJVbk130_assertion description "[The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP733343.RAX_qLHaruwRY0xLFfGNIm4SDUCSdeQHtRt3hJrhcJVbk130_provenance.